NCT04098068: Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have received at least one prior cancer therapy
Exclusions: Patient with known active central nervous system metastases and/or carcinomatous meningitis; Patients who have had prior treatment with anti-PD-1/PD-L1/2, anti-CD137, anti-OX40, anti-CD40, or anti-CTLA-4 antibodies

Comments are closed.

Up ↑